Robert Klein convinced Californians to part with $3 billion of their taxes to fund stem cell research. Proposition 71, the state referendum he championed, was handily passed by state voters in 2004, creating the largest source of embryonic stem cell funding in the world.

Klein, a Stanford-educated lawyer, transformed himself into a full-time medical research activist from a real estate investment banker after his son Jordan was diagnosed with juvenile diabetes in 2001. Now he’s the chairman of the Independent Citizens Oversight Committee (ICOC), the 29-member body that oversees the California Institute for Regenerative Medicine (CIRM), the state agency created by his proposition. Klein won state funding by stressing that embryonic stem cell research is vital to fighting disease?from the rare and always fatal (neurodegenerative ailments like ALS) to the alarmingly common and chronic (diabetes). But Klein maintains the rhetoric and stance of a combative underdog. On a recent sunny spring weekend he huddled in a darkened San Francisco conference room with 80 or so patient-activists, rallying them against conservative and right-to-life politicians and groups who have criminalized such research in some states. “How many people do you think it takes to start a revolution?” he asked the crowd. “I can tell you, it’s many less than the people in this room.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]